Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, confirmed that its promoter Berhyanda Limited has filed a declaration stating no fresh encumbrance was created on its shares during the financial year 2025-26. The disclosure was submitted under Regulation 31(4) of the SEBI Takeover Regulations to both the BSE and the National Stock Exchange of India.
Berhyanda Limited stated that neither it nor the persons acting in concert with it have made any encumbrance on the shares of Cohance Lifesciences, directly or indirectly, beyond what was already disclosed during the financial year 2025-26. The declaration was dated April 7, 2026, and was submitted to the exchanges on June 23, 2026, under the trading symbol COHANCE.
The persons acting in concert covered under this declaration include Jusmiral Holdings Limited, Berhyanda Midco Limited, and Jusmiral Midco Limited. All four entities are classified as promoters of Cohance Lifesciences, which was formerly known as Suven Pharmaceuticals Limited. The declaration was signed by Christodoulos Patsalides, Director of Berhyanda Limited.
Under Regulation 31(4) of the SEBI Takeover Regulations, promoters and persons acting in concert must disclose any encumbrance on shares of the target company that has not been previously reported during the financial year. Encumbrance includes pledges, liens, and other forms of charges created against the shares held by the promoter group.
The scrip code assigned to Cohance Lifesciences on the BSE is 543064. Cohance Lifesciences trades under the symbol COHANCE on the National Stock Exchange of India.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.